Regulatory documents revealed Pfizer didn’t thoroughly examine biodistribution and pharmacokinetics issues relating to its vaccine before submitting the vaccine to the European Medicines Agency (EMA) for review.In fact, in key studies — called biodistribution studies, which are designed to test where an injected compound travels in the body, and which tissues or organs it accumulates in — Pfizer did not use the commercial vaccine (BNT162b2) but instead relied on a “surrogate” mRNA that produced the luciferase protein.
Continue reading ➤ Pfizer Skipped Critical Testing and Cut Corners on Quality Standards, Documents Reveal • Children’s Health Defense
Total Page Visits: 248 - Today Page Visits: 1
